follow pre-announc earlier month investor enter earn
call larg focus guidanc believ enough maintain
sentiment view setup share favor given multitud driver
upsid maintain outperform rate
manag guid organ sale growth estim
adjust ep guidanc bracket consensu estim
guidanc contempl currenc tailwind advers
price consist modest tax rate increas pre-
announc provid actual figur tax rate state
would like modest headwind would like off-set strength
core busi oper margin expans expect
bridg result guidanc manag call tailwind includ
fx progress recoveri continu momentum mako regard
notion potenti conserv guid manag call potenti
headwind spine market chang tax law lack full visibl
despit growth comp believ top-lin guidanc reason
given grow halo effect mako balanc strength across geographi
busi segment expect continu execut earli de-
risk back-half year forese upward revis guidanc especi
spine market show sign improv addit guidanc issu
ep guidanc mid-point about-in line consensu
estim
mako launch progress halo effect continu
mako instal total robot global also
compani first robot sale japan approv total knee applic
expect japan end year mako instal increas sequenti throughout
robot robot robot
continu see roughli instal occur competit account
compani below-averag market share give opportun
get foot door sell entir recon product line respect train
surgeon train system includ approxim
enabl mako total knee procedur nearli
repres surgeon use triathlon total knee first time
halo effect pull knee sale continu note
primari knee mako total knee account grew five time rate account without
mako total knee applic mako util rate increas year year
sequenti compani also note upgrad robot field
progress ahead plan upgrad repres major focu perhap
modest expens capit sale given time requir coordin upgrad
pleas see page report import disclosur
outperform rate center belief diversifi busi model margin
expans initi strategi off-set continu price util
headwind ortho spine market expect deliv top-tier top-
bottom-lin growth vs med tech peer revenu growth ep growth
achiev opinion importantli think well posit ou emerg
market expans china lead way also see double-digit growth potenti
trauma extrem line instrument neurovascular devic among
market develop share gain
trevo follow recent releas
maintain share diversifi ortho
segment stabil spine
reduct cogs/year
 drive sale growth
irr year target close
better-than-expect ww share gain
ortho spine trauma busi
rapid expans better-than-
expect adopt emerg market
mark
ortho spine market worsen
share loss ortho spine mkt
portfolio outsid recon busi
fail provid suffici offset
ep growth fall short growth target
next five year
lead global medic technolog compani offer divers portfolio
reconstruct joint spine medic surgic neurovascular product compani
three major busi segment reconstruct medsurg neurotechnolog
spine product offer includ implant joint replac trauma spine-bas
surgeri surgic equip navig system endoscop commun
system patient handl emerg medic equip endovascular devic
treatment stroke coil treatment aneurysm major
global presenc look increas sale emerg market includ china
acquisit trauson acquisit mako surgic late brought
innov robot technolog platform recon busi earli
acquisit physio-control bolster medsurg busi
knee strength remain appar
continu expect entir us instal base upgrad strategi
complet sometim outlook year encourag
place mako robot hospit repres custom
base expect double-digit growth system instal aforement
progress upgrad process expans outsid accumul
clinic evid mako later year believ upcom aao meet
take place earli march anoth high-profil event mako build surgeon
interest cementless knee continu major driver well recent receiv
clearanc cementless mako total knee triathlon tritanium compani
note approxim total knee done cementless knee
larg major still open procedur earli adopt robot cementless
knee command price premium gain signific ground reach
penetr believ share continu trend higher compani stress
enthusiasm mako cementless applic sinc precis cut provid
robot increas press-fit abil implant
report revenu ep in-lin syk pre-
announc earli januari segment orthopaed grew organ medsurg
neurotechnolog spine grew growth led way
organ sale orthopaed growth driven
momentum trauma extrem knee
respect within categori result propel print product
foot ankl portfolio mako medsurg strength highlight strength
power tool star shield product endoscopi although full suit product
return market continu regain market share product line
still headwind quarter lost sale howev better
manag intern estim rebound sale continu progress
favor neurotechnolog spine especi strong quarter reflect
momentum neurovascular cmf product portfolio spine busi
despit continu soft broader market continu robust demand
interbodi titanium product
margin expans may scrutin potenti upsid
gross margin in-lin prior year quarter impact
hurrican maria unfavor price mix acquisit creat drag
result oper margin yoy suffer similar headwind although
manag note margin would expand adjust one-tim
expens relat puerto rico loss sale exclud dilut
look forward manag anticip oper margin expans
inclus margin dilut entellu novadaq rang consist
annual long-term margin expans profil effici measur includ
ctg program expect play critic role drive expans despit
on-going invest ctg erp effort also benefit revers mani
aforement headwind translat rang manag
express strong level hit mid-point higher driver toward upsid
rang includ acceler cost save program relat item hr
financ share servic although margin expans guidanc in-lin
long-held annual target believ could sourc disappoint
investor given declin said appear manag
built level caution guidanc believ leav room upsid
compel increas pt
continu believ diversifi busi model consist organ top
line growth margin expans initi strategi coupl improv trend
ortho franchis mako halo effect top perform neurovascular
franchis allow deliv upper echelon perform throughout
beyond remain track maintain one top spot medic devic
growth ladder cc growth sustain back product cycl
includ mako total knee applic cash ep estim bring us
impli new price target share previous given rais
confid sustain top-lin growth trajectori
potenti upward revis out-year ep estim set stronger om
expans stori reiter outperform rate
figur revenu result vs cowen estim consensu
compani report thomson eikon cowen compani
select revenu metric mm actualcowen varianceww trauma healthcar cowen
figur result vs cowen estim consensu
compani report cowen compani
incom statement mm except profit net per count cowen
compani report thomson eikon cowen compani
mm except devic ex-med devic gener oper profit profit includ net non-gaap net earn per non-gaap earn per earn per cowen
compani report cowen compani
growth currenc state growth currenc state growth growth currenc tha growth currenc growth currenc state growth currenc state growth growth currenc knee growth currenc growth currenc growth growth currenc growth currenc state growth currenc growth currenc cowen
compani report cowen compani
growth currenc growth growth currenc growth currenc growth growth currenc growth currenc growth growth currenc growth currenc growth currenc growth currenc growth currenc growth currenc growth currenc growth currenc growth currenc growth currenc growth currenc growth currenc growth currenc growth currenc growth currenc growth currenc cowen
compani report cowen compani
growth currenc growth growth currenc growth growth currenc growth currenc growth currenc growth currenc growth currenc growth currenc growth growth currenc growth currenc growth currenc growth currenc spine growth currenc growth growth growth currenc growth growth currenc inorgan sell day report growth report growth ex-inorgan sell organ growth organ growth ex-fx ex-sel cowen
valuat methodolog primarili base current year forward year ev/sal
ev/ebitda multipl well current year forward price-to-earnings multipl total return/p
ratio market cap/fre cash flow metric dividend yield comp
orthoped industri risk continu util pressur account
organ play bigger role health care deliveri competit dynam global
potenti regulatori delay reject failur devic clinic trial econom
sensit price pressur and/or weaken consum demand develop market
econom and/or polit uncertainti emerg market intellectu properti
deeper util pressur europ competit dynam global
potenti regulatori delay reject failur devic clinic trial econom
sensit price pressur and/or weaken demand develop market econom
and/or polit uncertainti emerg market fluctuat foreign exchang
